Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner

Table 2 OAVs with a 24 bp deletion in E1A

Cancer	Vector	Construct	Transgene/Feature	Administration	Phase	ClinicalTrials.gov ID	Ref.	Combination
Solid tumor	CAdVEC	Ad5-∆24		Intratumoral	Phase I	NCT03740256	[71]	HER2-CAR-T
Breast cancer				Intravenous	Preclinical		[72]
Solid tumor		Ad5-∆24-GM-CSF	GM-CSF	Intratumoral, intracavitary	Preclinical		[73]
Glioma	DNX-2401	Ad5-∆24-RGD4C		Intratumoral, intramural	Phase I	NCT03178032 NCT01956734	[74, 75]	Radiotherapy, chemotherapy
Glioblastoma	DNX-2401	Ad5-∆24-RGD4C		Intratumoral	Phase II	NCT02798406	[76]	Pembrolizumab
Glioma	DNX-2440	Ad5-Δ24-RGD4C-OX40L	OX40L	Intratumoral	Phase I	NCT03714334
Colorectal liver metastasis	DNX-2440	Ad5-Δ24-RGD4C-OX40L	OX40L	Intratumoral	Phase I	NCT04714983
Lung cancer		Exosome-Ad5-∆24-CpG	Exosome delivery, CpG	Intravenous	Preclinical		[77, 78]	Paclitaxel

ISSN: 2050-7771